Comparative effectiveness research for antipsychotic medications: How much is enough

David O. Meltzer, Anirban Basu, Herbert Y. Meltzer

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Second-generation antipsychotics have attracted practitioners' and policymakers' attention, because of concerns over their health effects and costs. Comparative effectiveness data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) - a high-profile National Institutes of Health (NIH)-funded study - have been used to argue for restricting coverage for these costly drugs. But concerns about the design of CATIE and its associated cost-effectiveness analysis and uncertainty about the precision of these findings raise questions about this interpretation. Our work suggests that additional research to increase the precision of comparisons of the effectiveness of antipsychotics would be well worth the cost.

Original languageEnglish (US)
Pages (from-to)w794-w808
JournalHealth Affairs
Volume28
Issue number5
DOIs
StatePublished - Sep 2009

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Comparative effectiveness research for antipsychotic medications: How much is enough'. Together they form a unique fingerprint.

Cite this